PROBLEM TO BE SOLVED : To provide a pharmaceutical composition for treating the core symptoms of autism spectrum disorder (ASD) and associated symptoms including learning disabilities, language impairment and impairments in executive functioning that can be associated with the disease in patients with ASD (and particularly in phenotype 1 patients--a subcategory of patients presenting with specific differentiating clinical sets of signs and symptoms). SOLUTION : The pharmaceutical composition comprises a substance capable of raising intracellular cAMP levels, and a substance capable of modulating intracellular calcium concentration. The substance capable of raising intracellular cAMP levels is a PDE inhibitor, which PDE inhibitor is ibudilast. The substance capable of modulating intracellular calcium concentration is bumetanide. SELECTED DRAWING : None COPYRIGHT : (C)2019, JPO&INPIT